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Abstract
Blastic plasmacytoid dendritic cell neoplasm
is a rare, aggressive tumor characterized by
skin and/or marrow infiltration by CD4+ CD56+
cells. Historically, the tumor was variably
thought to arise from either monocytes, T cells
or NK cells giving rise to terms such as
CD4+/CD56+ acute monoblastic leukemia, pri-
mary cutaneous CD4+/CD56+ hematodermic
tumor and blastic NK-cell lymphoma. Whilst
considerable progress has been made in
understanding the histogenesis, the best
modality of treatment remains to be defined.
We are therefore reporting this case which was
successfully treated with a T-deplete allogene-
ic transplant and the patient is currently alive
and in remission 4 years post transplant.
Introduction
Blastic plasmacytoid dendritic cell neoplasm
(BPDCN) is a rare, aggressive tumor charac-
terized by skin and/or marrow infiltration by
CD4+ CD56+ cells. Historically, the tumor was
variably thought to arise from either mono-
cytes, T cells or NK cells giving rise to terms
such as CD4+CD56+ acute monoblastic
leukemia, primary cutaneous CD4+/CD56+
hematodermic tumor and Blastic NK-cell lym-
phoma. It is now believed that these tumors
arise from plasmablastic dendritic cells (also
called type 2 dendritic cells, DC2) which have a
major role to play in antiviral immunity.1
Whilst considerable progress has been made in
understanding the histogenesis, the best
modality of treatment remains to be defined.
Prognosis remains poor with median survival
of only a few months as the tumor exhibits a
progressive course despite initial response to
chemotherapy.
Case Report
We report a 62 year old retired postman with
a Karnofsky score of 100, who presented in
December 2008 with a 6 month history of a
slowly growing, painless, discolored skin
lesion on his upper back. Physical examination
revealed a 4 cm nodular, raised bruise like
lesion (Figure 1). There was no associated
lymphadenopathy or hepatosplenomegaly.
Initial investigations showed pancytopenia
with a hemoglobin 12.1 g/mL, white cell count
1.7×109/mL, platelets 96×109/mL and neu-
trophils 0.5×109/mL. Bone marrow was
markedly hypercellular with a diffuse infiltrate
of large atypical lymphoblastoid cells display-
ing prominent nuclear folding and scant
esinophilic cytoplasm (Figure 2). Immuno -
phenotyping revealed a 73% clone of CD4+
CD56+ cells. Immunostaining of the bone mar-
row biopsy showed tumor cells to be positive
for CD123, BDCA2, CD4, CD56, CD45, CD43,
HLADR, CD33, and CD99. The cells were focal-
ly positive for CD117 and CD68R and negative
for CD34, TdT, CD20, CD79a, CD3, CD5, CD2,
CD7, CD8, CD57, CD30, myeloperoxidase,
CD13, CD14, CD16, CD11c, CD163, perforin,
granzyme B, and CD138. Ki-67 expression was
seen in about 50% cells. In situ hybridization
for Epstein-Barr virus encoded RNA (EBER)
was negative. Based on these findings, a diag-
nosis of blastic plasmacytoid dendritic cell neo-
plasm was made. 
The patient was treated with one course each
of CODOX-M (cyclophosphamide, vincristine,
doxorubicin and methotrexate) and IVAC (ifos-
famide, etoposide and cytarabine) chemothera-
py. He was in complete remission following this
treatment with regression of the skin lesion and
morphological and immunophenotypic remis-
sion in the bone marrow. As consolidation, he
received a reduced intensity allogeneic stem
cell transplant from a fully HLA matched unre-
lated donor. The patient was conditioned with
fludarabine (30 mg/m2 for 5 days), melphalan
(140 mg/m2 - single dose) and alemtuzumab (25
mg - 2 doses on days 2 and 1). Ciclosporin was
used as graft versus host disease (GvHD) pro-
phylaxis. Stem cell dose was 6×106 CD34
cells/kg and neutrophil engraftment (neut>0.5)
occurred on D+14 while platelet engraftment
occurred on D+20 (PLT>20 unsupported). He
had grade II skin GvHD post transplant which
responded to systemic steroids with complete
resolution. Bone marrow assessment 3 months
post-transplant confirmed continuing complete
remission. 
He is currently well, alive and in remission
49 months from initial diagnosis (44 months
post-transplant) with full donor chimerism in
both whole blood and T cell compartments.
Donor lymphocyte infusions were not adminis-
tered at any stage post transplant.
Discussion
BPDCN is a disease of the elderly with 70% of
the cases occurring in patients older than 50
years. 90% present with cutaneous bruise-like
lesions or asymptomatic nodules/plaques.
Associated nodal and splenic involvement is
also well known. Peripheral blood and/or mar-
row involvement is seen in 60-90% patients
with cytopenias being the commonest presenta-
tion.1,2 Marrow shows heavy infiltration with
neoplastic cells which co-express CD4, CD56,
CD45RA, CD43, CD303, and CLA,3 with varying
expression of CD68, TDt, CD36, CD7 and HLA-
DR. Expression of CD123 [Interleukin (IL)-3
receptor  chain], and TCL1 (an AKT kinase reg-
ulator and lymphoid protooncogene), supports
DC2 cell of origin.4 Complex karyotype is com-
mon with recurring abnormalities including
deletions of 5q, 12q and 6q and loss of chromo-
somes 13, 15 and 9 as the 6.2,5 Skin biopsy typi-
cally reveals a dermal infiltrate with a periad-
nexal distribution. Differentiation form cuta-
neous T-cell lymphoma, cutaneous NK cell lym-
phoma and skin involvement by myelomonocyt-
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ic leukemia is based on pattern of involvement,
immunophenotype, T cell receptor (TCR) gene
rearrangements and positivity for EBV. Some
cases of BPDCN have relapsed with an acute
myelomonocytic leukemia type clinical picture
and the exact relationship between these dis-
eases is not known. 
Characteristically the tumor exhibits a pro-
gressive course despite initial response to
variety of chemotherapy schedules, with a
median time to progression of nine to 11
months and median survival of 13 months.1
Feuillard et al. published the 1st large series of
23 patients with CD4+CD56+ malignancies
treated with a variety of chemotherapy proto-
cols. 86% patients achieved complete remis-
sion (CR) but most relapsed with a median
time to relapse of 9 months. Three patients
had an allogeneic transplant in 1st complete
remission (CR), with one patient relapsing at
12 months.6 Patrella et al.7 and Reichard et al.8
published the 2 other big series with 30 and 10
cases respectively. In the first publication 75%
of patients responded to radiotherapy and/or
chemotherapy but 90% cases relapsed with
median time to relapse being 11 months. Only
3 of the 30 patients were alive with median
overall survival (OS) being 14 months. None of
the patients had an allogeneic transplant.1
Reimer et al.9 evaluated 97 patients treated
with either i) chemotherapy less intensive
than CHOP, ii) CHOP and CHOP-like regi-
mens, iii) regimens used for acute leukemia
and iv) autologous stem cell transplantation.
Of the 97 patients, six received an allogeneic
stem cell transplant, four with TBI based con-
ditioning. Only two of the six patients relapsed
(with median OS of 38.5 months). In an age-
adjusted evaluation, only allogeneic stem cell
transplantation in first CR showed significant
superiority in terms of overall survival to all
other treatments in patients <60 years. Piccin
et al.5 reported a patient who was successfully
treated for BPDCN with a complex karyotype
on an AML based regimen followed by an allo-
geneic stem cell transplant. In the pediatric
setting Sakashita et al.10 reported a child with
BPDCN treated with acute lymphoblastic
leukemia-type regimen with skin and
leukemic involvement followed by allogeneic
stem cell transplant with a myeloablative pro-
tocol. In their review of 33 cases of pediatric
BPDCN, the over survival was significantly
lower in the patients with skin manifestation
than those without cutaneous involvement and
those patients with poor prognosis seemed
more likely to benefit from an allogeneic stem
cell transplant in first remission which resem-
bles the characteristics of our patients.
The first patient we could find in reported lit-
erature who had a non-myeloablative allogeneic
stem cell transplant for BPDCN was reported by
Amor et al.11 We believe the patient we have
reported in this review is the 2nd case treated
with a reduced intensity conditioning
Alemtuzumab based T-deplete conditioned allo-
geneic transplant. In light of our experience,
reduced intensity T-deplete allogeneic stem cell
transplant could be considered if age, perform-
ance status or comorbidities does not allow the
use of a TBI based protocol. It appears a promis-
ing alternative in older patients with BPDCN
and needs to be explored in future studies to
improve the outcome in this disease.
References
1. Herling M, Jones D. CD4+/CD56+ hemato-
dermic tumor. The features of an evolving
entity and its relationship to dendritic
cells. Am J Clin Pathol 2007;127:687-700.
2. Leroux D, Mugneret F, Callanan M, et al.
CD4+, CD56+ DC2 acute leukemia is
characterized by recurrent clonal chromo-
somal changes affecting 6 major targets: a
study of 21 cases by the Groupe Français
de Cytogénétique Hématologique. Blood
2002;99:4154-9.
3. Faceheti F, Jones DM, Petrella T. In:
Swerdlow SH, Campo E, Harris N, et al,
eds. WHO classification of tumours of
haematopoietic and lymphoid tissues. 4th
ed. Lyon: IARC Press; 2008.
Case Report
[page 5]
Figure 1. Bruise-like lesion on left side of thoracic vertebrae.
Figure 2. Bone marrow trephine showing medium sized cells with
polymorphic, angulated nuclei with moderately basophilic chro-
matin and scant eosinophilic cytoplasm. Morphologically these
cells resemble atypical lymphocytes. Mitoses are numerous
(H&E, 63×).
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